塞马格卢提德对肥胖相关心力衰竭患者心脏结构和功能的影响
Scott D Solomon1, John W Ostrominski2, Xiaowen Wang1
1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Journal of the American College of Cardiology
|September 1, 2024
概括
在患有与肥胖有关的心力衰竭患者中,每周一次的西马格卢提德 (2.4毫克) 改善了心脏结构,并保留了喷射分数 (HFpEF). 该研究显示左心房重塑减少和右心室扩大,表明疾病修饰效应.
科学领域:
- 心脏病学 心脏病学
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 肥胖是不良心脏改造和心力衰竭 (HF) 的重要危险因素.
- 塞马格卢提德 (每周2.4毫克) 在肥胖相关的HFpEF中显示出对HF症状和体重减轻有好处.
- 塞马格卢提德对该人群心脏结构和功能的影响以前是未知的.
研究的目的:
- 评估每周服用一次塞马格卢提德 (2.4毫克) 与安慰剂对心脏结构和功能的影响.
- 评估与肥胖相关的HFpEF患者心声学参数的变化.
- 为了确定塞马格卢提德是否可以在这个患者群体中修改心脏重塑.
主要方法:
- 一项涉及491名参与者的STEP-HFpEF计划的心声回声学子研究.
- 在基线和52周评估心脏结构和功能.
- 主要结局:左心房 (LA) 体积的变化;次要结局:其他心声学参数. 使用了共变量分析.
主要成果:
- 与安慰剂相比,塞马格卢提德显著减轻了左心房 (LA) 重建和右心室 (RV) 扩张的进展.
- 随着西马格卢提德治疗,观察到E波速度,E/A比率和E/e'平均值的改善.
- 较大的体重减轻与较大的LA体积减少相关,但塞马格卢提德并没有显著改变左心室尺寸,质量或缩功能.
结论:
- 在患有与肥胖相关的HFpEF的患者中,塞马格卢提德治疗证明了对不良心脏重塑的改善.
- 这些发现表明,塞马格卢提德可能对与肥胖相关的HFpEF具有疾病修饰性.
- 这项研究提供了进一步的证据,证明塞马格卢提德在这种特定患者群体中的心血管益处.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:24Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183